Intervention not reported
Adverse events Participants (n) reported serious adverse events · patients with treating osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain (short term) WOMAC scale from 0 to 20 points (higher is worse pain). · patients with osteoarthritis
1 finding from 1 review
Function (short‐term) WOMAC scale from: 0 to 100 (higher is worse function). · patients with osteoarthritis
1 finding from 1 review
Adverse events Participants (n) reported adverse events · patients with osteoarthritis
Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported adverse events compared with chondroitin sulphate (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with osteoarthritis
1 finding from 1 review
Adverse events Participants (n) reported serious adverse events · patients with osteoarthritis
Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported serious adverse events compared with chondroitin sulphate (low certainty).
1 finding from 1 review
Radiographic joint changes · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Radiographic joint changes · patients with treating osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · patients with treating osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pain Global pain VAS 0‐100 (higher scores mean worse) · patients with treating osteoarthritis
1 finding from 1 review
Intervention not reported
Function WOMAC‐VAS (Function) · patients with treating osteoarthritis
1 finding from 1 review
Intervention not reported
At least 50% of maximum pain relief over 4 to 6 hours · adults with moderate or severe acute postoperative pain
The intervention leads to higher at least 50% of maximum pain relief over 4 to 6 hours (high certainty).
1 finding from 1 review
RR 5.6 [4, 7.8]
Studies not reported
High
Intervention not reported
Participants with at least 1 adverse event · adults with moderate or severe acute postoperative pain
The intervention showed no clear difference in participants with at least 1 adverse event (moderate certainty).
1 finding from 1 review
RR 0.93 [0.74, 1.2]
Studies not reported
Moderate
Intervention not reported
Participants with a serious adverse event · adults with moderate or severe acute postoperative pain
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Deaths · adults with moderate or severe acute postoperative pain
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Proportion of patients who are seizure free between 4‐40 weeks · Patients with a clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who are seizure free between 4‐40 weeks (very low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients with an adverse event · Patients between three and 12 years old with clinical and EEG diagnosis of BECTS
The intervention showed no clear difference in proportion of patients with an adverse event (low certainty).
1 finding from 1 review
Intervention not reported
Changes in cognitive function · Patients between three and 12 years old with clinical and EEG diagnosis of BECTS
1 finding from 1 review
Intervention not reported
Proportion of patients who are seizure free at 28 weeks · Patients between five and 15 years old with a diagnosis of BECTS
The intervention showed no clear difference in proportion of patients who are seizure free at 28 weeks (low certainty).
1 finding from 1 review